Regenerative medicine is the branch of medicine that develops methods to regrow, repair or replace damaged or diseased cells, organs or tissues. Regenerative medicine includes the generation and ...

THR-beta agonists are the only medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe ...

Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal ...

Personalized medicine is a therapeutic approach involving the use of an individual’s genetic and epigenetic information to tailor drug therapy or preventive care. We developed an endothelial ...

The Race and Medicine collection reflects NEJM’s commitment to understanding and combating racism as a public health and human rights crisis. Our commitment to antiracism includes efforts to ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges.

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced its financial results for 2024, marking a pivotal year highlighted by the FDA approval and successful launch of Rezdiffra ...

10. Rezdiffra for metabolic dysfunction-associated Steatohepatitis (MASH) Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) was granted FDA approval on March 14, 2024, for the treatment of metabolic ...

By the end of last year, more than 11,800 patients were on Rezdiffra. In a conference call ... s consistent with other top tier specialty medicine launches,” Sibold added. On the prescriber ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust financial performance with significant milestones in Rezdiffra's launch and market penetration.

We secured FDA approval for Rezdiffra, the first medicine approved for MASH, in March; executed a first-in-disease launch with remarkable results; and are well positioned for strong performance again ...